Studies of MJ in four different cell types (murine melanoma: B16, murine colon carcinoma: CT26, murine B cell leukemia: BCL1, human T lymphoblastic leukemia cell line: Molt-4) revealed that MJ at a dose of 3 mM and incubation period of 30 minutes dissociates HKII from VDAC and, as a result, inhibits the activity of HKII [172]. Here, HK2 is linked to melanoma.